DRKS00011932已完成2 期
Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients - MARTA
niversitätsklinikum FreiburgMedizinische Klinik IHämatologie, Onkologie und Stammzelltransplantation0 个研究点目标入组 53 人开始时间: 2017年8月18日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 53
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- N/a: Single Arm Study
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 65 Years 至 one（—）
- 性别
- All
入选标准
- •Key inclusion criteria:
- •1. Immunocompetent patients with newly-diagnosed primary central nervous system B-cell lymphoma.
- •2. Age > 65 years plus patients between 65-70 years, who are not eligible for treatment within the MATRix/IELSG43 trial.
- •3. Histologically or cytologically assessed diagnosis of B-cell lymphoma by local pathologist.
- •4. Diagnostic sample obtained by stereotactic or surgical biopsy, CSF cytology examination or vitrectomy.
- •5. Disease exclusively located in the CNS.
- •6. At least one measurable lesion.
- •7. ECOG-Performance Status = 2.
- •8. Patients eligible for intensive treatment according to physician´s choice.
- •9. Written informed consent obtained according to international guidelines and local laws by patient or authorized legal representative in case patient is temporarily legally not competent due to his or her disease.
排除标准
- •Key exclusion criteria:
- •1. Congenital or acquired immunodeficiency.
- •2. Systemic lymphoma manifestation (outside the CNS).
- •3. Isolated ocular lymphoma without manifestation in the brain parenchyma or spinal cord.
- •4. Previous or concurrent malignancies with the exception of surgically cured carcinoma in-situ of the cervix, carcinoma of the skin or other kinds of cancer without evidence of disease for at least 5 years.
- •5. Previous systemic Non-Hodgkin lymphoma at any time.
- •6. Inadequate renal function (creatinine clearance <60 ml/min).
- •7. Inadequate hepatic, cardiac or pulmonary function according to physician`s decision.
- •8. Active hepatitis B or C disease.
- •9. HIV infection, previous organ transplantation or other clinical evident form of immunodeficiency.
- •10. Concurrent treatment with other experimental drugs or participation in a clinical trial within the last thirty days before the start of this study.
- •11. Third space fluid accumulation >500 ml.
- •12. Hypersensitivity to study treatment or any component of the formulation.
- •13. Taking any medications likely to cause interactions with the study medication.
- •14. Known or persistent abuse of medication, drugs or alcohol.
- •15. Patient without legal capacity and who is unable to understand the nature, significance and consequences of the study and without designated legal representative.
- •16. Persons who are in a relationship of dependency/employment to the sponsor and/ or investigator.
- •17. Any familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.
研究者
相似试验
进行中（未招募）
1 期
The principal objective of the study is to investigate tolerability of highdosechemotherapy and autologous stem cell transplant in elderly patientsolder than 65 years with newly-diagnosed or relapsed primary lymphomasof the central nervous system.Primary central nervous system lymphoma (PCNSL) is an aggressiveNon-Hodgkin Lymphoma (NHL) mostly of B-cell origin, which exclusivelyinvades the central nervous system compartment. It accounts for 3% to4% of all primary brain tumours and 4% to 6% of extra-nodallymphomas. The incidence of PCNSL in immunocompetent patients hasbeen steadily increasing over the last 30 years. Patients older than 60years account for more than 50% of all PCNSL cases.EUCTR2016-001628-72-DEMedical Center - University of Freiburg51
招募中
3 期
Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line treatment in elderly primary CNS lymphoma patients – a randomized phase III trialDiseases [C] - Blood and lymphatic diseases [C15]DRKS00024085IVERSITÄTSKLINIKUM FREIBURG; Klinik für Innere Medizin I Schwerpunkt Hämatologie, Onkologie und Stammzelltransplantation260
招募中
1 期
Age-adapted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy and maintenance therapy in fit elderly patients* with initial diagnosis of primary cerebral lymphoma.EUCTR2020-001181-10-ATMedical Center - University of Freiburg310
进行中（未招募）
1 期
Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line treatment in elderly primary CNS lymphoma patients – a randomized phase III trial - PRIMA-CNSPrimary diffuse large B-cell lymphoma of the central nervous system(PCNSL) is a rare lymphoma affecting only the central nervous systemcompartment. PCNSL patients are typically 60 years or older and havepoor prognoses. Considering the poor prognosis of this patientpopulation, this randomised phase III trial proposal is of great clinicalimportance to provide patients optimal treatment.CTIS2024-512320-11-00Medical Center - University Of Freiburg248
进行中（未招募）
1 期
High-dose chemotherapy and autologous stem cell transplant or consolidating conventional chemotherapy in primary CNS lymphoma -randomized phase III trialPrimary CNS lymphoma (PCNSL) accounts for 1 to 2% of all Non-Hodgkin's lymphomas (NHL) and for 2 to 7% of all primary CNS tumors.It's incidence has increased over the past 30 years, particularly in immunocompetent individuals. Over 90% of PCNSL are lymphomas of Bcell origin, accounting to the subtype diffuse large B-cell lymphoma.(DLBCL). Prognosis without treatment resembles that of systemic highgrade NHL, and the median survival of untreated patients with PCNSL is approximately 3 months.MedDRA version: 21.0Level: PTClassification code 10007953Term: Central nervous system lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-000620-17-ITCITY OF STUTTGART, REPRESENTED BY KLINIKUM STUTTGART250